Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | Zendy

AI Assistant Blog Pricing

Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.